- Humanigen will release P3 clinical data for Lenzilumab in COVID-19 in late March.
- We believe that based on the pathophysiology, existing clinical data with GM-CSF blockage and the trial design, the study is more likely to be a success than not.
- In case of a positive trial readout, the stock could appreciate very substantially (potentially >500%).
- Please be mindful of the risk ahead of this binary. We believe that the stock could decline as much as 80% if the trial fails.
For further details see:
Humanigen COVID-19 Lenzilumab Trial Is Designed For Success, Data In March